This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Romiplostim (AMG-531) for idiopathic thrombocytopenia – refractory

< Back

Romiplostim (AMG-531) for idiopathic thrombocytopenia – refractory


Haematology and Blood Products

August 2006

Romiplostim (AMG531) is a thrombopoietin agonist, platelet growth factor that stimulates platelet production by binding to the myeloproliferative leukaemia receptor. It increases the production of platelets by stimulating the differentiation and proliferation of megakaryocytes. It is also in phase II trials for chemotherapy induced thrombocytopenia and myelodysplastic syndrome. Developer Amgen Stage of development and availability in EU/UK Pre-registration in EU (drugs) CE marked, but not yet launched Phase III clinical trials or or available in UK equivalent Licence or CE mark application in Launch or use in UK/EU likely Licence or CE mark application UK/EU likely within 24 months within 12 months in UK/EU likely within 12 months Established product, but this is a Other, please specify Launch or use in UK/EU likely new indication in development within 24 months

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

PDF Report


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts